Lifeline Biotechnologies Stock Net Income
| LLBO Stock | USD 0.0005 0.0002 28.57% |
As of the 28th of January, Lifeline Biotechnologies secures the Mean Deviation of 9.87, risk adjusted performance of 0.0313, and Downside Deviation of 21.96. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lifeline Biotechnologies, as well as the relationship between them.
Lifeline Biotechnologies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lifeline Biotechnologies' valuation are provided below:Lifeline Biotechnologies does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Lifeline |
Lifeline Biotechnologies 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lifeline Biotechnologies' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lifeline Biotechnologies.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Lifeline Biotechnologies on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Lifeline Biotechnologies or generate 0.0% return on investment in Lifeline Biotechnologies over 90 days. Lifeline Biotechnologies is related to or competes with Cannabix Technologies, C21 Investments, and Relief Therapeutics. Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States More
Lifeline Biotechnologies Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lifeline Biotechnologies' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lifeline Biotechnologies upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 21.96 | |||
| Information Ratio | 0.0245 | |||
| Maximum Drawdown | 58.33 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 28.57 |
Lifeline Biotechnologies Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lifeline Biotechnologies' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lifeline Biotechnologies' standard deviation. In reality, there are many statistical measures that can use Lifeline Biotechnologies historical prices to predict the future Lifeline Biotechnologies' volatility.| Risk Adjusted Performance | 0.0313 | |||
| Jensen Alpha | 0.5034 | |||
| Total Risk Alpha | (1.00) | |||
| Sortino Ratio | 0.0172 | |||
| Treynor Ratio | (0.54) |
Lifeline Biotechnologies January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0313 | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 9.87 | |||
| Semi Deviation | 11.48 | |||
| Downside Deviation | 21.96 | |||
| Coefficient Of Variation | 3373.38 | |||
| Standard Deviation | 15.39 | |||
| Variance | 236.99 | |||
| Information Ratio | 0.0245 | |||
| Jensen Alpha | 0.5034 | |||
| Total Risk Alpha | (1.00) | |||
| Sortino Ratio | 0.0172 | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 58.33 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 28.57 | |||
| Downside Variance | 482.05 | |||
| Semi Variance | 131.86 | |||
| Expected Short fall | (23.72) | |||
| Skewness | 0.2594 | |||
| Kurtosis | 0.1763 |
Lifeline Biotechnologies Backtested Returns
As of now, Lifeline Pink Sheet is out of control. Lifeline Biotechnologies has Sharpe Ratio of close to zero, which conveys that the firm had a close to zero % return per unit of risk over the last 3 months. We have found thirty technical indicators for Lifeline Biotechnologies, which you can use to evaluate the volatility of the firm. Please verify Lifeline Biotechnologies' Downside Deviation of 21.96, mean deviation of 9.87, and Risk Adjusted Performance of 0.0313 to check out if the risk estimate we provide is consistent with the expected return of 0.11%. The company secures a Beta (Market Risk) of -0.82, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Lifeline Biotechnologies are expected to decrease at a much lower rate. During the bear market, Lifeline Biotechnologies is likely to outperform the market. Lifeline Biotechnologies right now secures a risk of 14.89%. Please verify Lifeline Biotechnologies total risk alpha and the relationship between the potential upside and day typical price , to decide if Lifeline Biotechnologies will be following its current price movements.
Auto-correlation | 0.38 |
Below average predictability
Lifeline Biotechnologies has below average predictability. Overlapping area represents the amount of predictability between Lifeline Biotechnologies time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lifeline Biotechnologies price movement. The serial correlation of 0.38 indicates that just about 38.0% of current Lifeline Biotechnologies price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.38 | |
| Spearman Rank Test | -0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Lifeline Biotechnologies reported net income of (574,268). This is 100.17% lower than that of the Healthcare sector and 100.24% lower than that of the Medical Devices industry. The net income for all United States stocks is 100.1% higher than that of the company.
Lifeline Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifeline Biotechnologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lifeline Biotechnologies could also be used in its relative valuation, which is a method of valuing Lifeline Biotechnologies by comparing valuation metrics of similar companies.Lifeline Biotechnologies is currently under evaluation in net income category among its peers.
Lifeline Fundamentals
| Current Valuation | 4.25 M | |||
| Net Income | (574.27 K) | |||
| Cash And Equivalents | 603.32 K | |||
| Total Debt | 448.07 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 8.42 X | |||
| Book Value Per Share | 0 X | |||
| Beta | -1.86 | |||
| Market Capitalization | 10.99 M | |||
| Total Asset | 6.72 M | |||
| Z Score | 14.4 | |||
| Net Asset | 6.72 M |
About Lifeline Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifeline Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifeline Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifeline Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lifeline Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifeline Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifeline Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving against Lifeline Pink Sheet
| 0.46 | CNOB | ConnectOne Bancorp Earnings Call Tomorrow | PairCorr |
| 0.45 | DCI | Donaldson | PairCorr |
| 0.44 | MDT | Medtronic PLC | PairCorr |
| 0.43 | BKKLY | Bangkok Bank PCL | PairCorr |
| 0.37 | DXCM | DexCom Inc | PairCorr |
The ability to find closely correlated positions to Lifeline Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifeline Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifeline Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifeline Biotechnologies to buy it.
The correlation of Lifeline Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifeline Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifeline Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifeline Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Lifeline Pink Sheet
Lifeline Biotechnologies financial ratios help investors to determine whether Lifeline Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lifeline with respect to the benefits of owning Lifeline Biotechnologies security.